Introduction
============

Inflammatory Bowel Disease (IBD) is a group of immune-mediated diseases mainly represented by Ulcerative colitis (UC) and Crohn's disease (CD) ([@B65]). IBD presents a multifactorial etiology driven by immunological disturbances, genetic alterations and the influence of environmental factors such as diet, lifestyle, socioeconomic development, intestinal dysbiotic microbiota, among other aspects ([@B7]). Current therapies are based on pharmacological approaches using traditional medicines such as aminosalicylates, corticosteroids, thiopurines, folic acid antagonists, or biological therapies, aiming at controlling inflammation besides reducing disease relapse ([@B88]). However, these approaches are not curative, and patients may become refractory or intolerant to them. In this context, therapies aiming at modulating the microbes inhabiting the human body, especially the intestine, have been suggested as one of the most promising strategies to treat immune-mediated diseases such as IBD ([@B74]; [@B2]). This is of particular interest because recent investigations demonstrate that conventional treatments fail to completely restore the normal microbiota of patients with IBD, even if associated with special diets ([@B61]). Though we understand the importance of other microbial interventions using symbiotics and prebiotics, for example, this review will focus on the human studies using fecal microbiota transplantation (FMT) and probiotics as strategies to restore the normal microbiota in IBD patients.

Intestinal Microbiota
=====================

Before addressing the role of FMT and probiotics in IBD, it is important to introduce how the intestinal microbiota is able to interact with the vertebrate host, thus influencing health and disease status. Despite the great distribution of microorganisms in different sites of the human body, the most diverse microbial species is found in the gastrointestinal tract (GIT) ([@B44]; [@B46]). More than 1000 microbial species, including bacteria, virus, and fungal, were identified in the human GIT ([@B98]). These commensal and symbiotic communities of microorganisms, also known as microbiota, are able to directly or indirectly influence local and systemic physiology of the human body, including but not limited to the immunologic, endocrine, and nervous systems ([@B60]). The composition of gut microbiota, in turn, can be influenced by different aspects such as diet, xenobiotics, lifestyle, and genetics ([@B34]; [@B104]). Thus, it is reasonable to assume the great impact that perturbations in the complex bidirectional relationship between vertebrate hosts and gut microbes may have on host physiology. Further, this complex interaction can also lead to the onset and maintenance of several diseases, including IBD ([@B22]). Though gut microbiota is colonized by different microorganisms (bacteria, fungi, archaea, and viruses), the term "microbiota" is often used to refer to bacterial species within the GIT, which represents more than 96% of the total microbial population ([@B98]). However, fungal and viral dysbiosis have also been implicated in IBD development ([@B61]; [@B21]).

To limit inappropriate activation in surfaces with great contact with microbes, like GIT, the human body has developed chemical and physical barriers to anatomically separate the microbiota from immune cells ([@B45]). However, this interface is not insurmountable and some commensal microorganisms are able to interact with the immune, endocrine and nervous systems ([@B14]). So far, two hypotheses were proposed to clarify the mechanisms concerning this interplay: the presence of pattern recognition receptors (PRR) in host cells sensing microbial associated molecular patterns (MAMPs)/danger associated molecular patterns (DAMPS), and the activity of microbial metabolites over different mammalian biological systems ([@B16]; [@B81]). In this context, it is possible to highlight the beneficial role of the polysaccharide A of *Bacteroides fragilis*, which is able to stimulate the differentiation and activity of regulatory T cells (Treg) in the gut ([@B19]). The presence of Tregs in intestine is of great contribution to the maintenance of a tolerant environment, thus avoiding unnecessary inflammation ([@B40]). Further, the production of immunoglobulin A (IgA) by intestinal plasma cells, which is crucial for the protection against pathobionts in intestine, is positively influenced by epithelium-associated bacteria such as *Mucispirillum* and segmented filamentous bacteria (SFB) ([@B12]). One of the most studied groups of microbiota-derived metabolites with protective effects toward the mammalian host is the short chain fatty acids (SCFAs) that are mainly derived from fermentation of dietary fibers ([@B82]). SCFAs are primarily represented by three compounds acetate, propionate and butyrate, which contribute to the integrity of intestinal epithelium besides directly influencing host metabolic and immune functions ([@B100]).

Intestinal Dysbiosis in the Pathogenesis of IBD
===============================================

Dysbiosis has been explored as a causative agent of several systemic and local diseases affecting GIT, including UC and CD ([@B57]). The gut microbial changes in IBD are summarized in Table [1](#T1){ref-type="table"}. In comparison to healthy subjects, IBD patients have reduced microbial composition (up to 25%), diversity, and richness with increased numbers of pathogenic/pathobionts microorganisms (e.g., Proteobacteria, Fusobacteria species, and *Ruminococcus gnavus --* Firmicutes) ([@B27]), and decreased numbers of beneficial microorganisms such as *Lachnospiraceae* (Firmicutes), *Bifidobacterium* species (Actinobacteria), *Roseburia* (Firmicutes), *Sutterella* (Proteobacteria) ([@B33]), and *Faecalibacterium prausnitzii* (Firmicutes), which are at least 10-fold reduced in IBD ([@B105]). To note, *F. prausnitzii* has been suggested as one of the major microbial components of human healthy intestinal microbiota representing almost 5% of the total bacterial population ([@B63]). This bacterium contributes to the maintenance of a regulatory environment in intestine through the production of butyrate, besides providing energy to colonocytes ([@B91]). The observation that intestinal microbes cooperate to the maintenance of epithelial integrity in intestine is of great importance since these mechanisms are frequently disrupted in IBD. One of the theories to explain the occurrence of dysbiosis in IBD relies on the inflammation. Results from both experimental and clinical investigations associate inflammatory responses and perturbations in microbial composition in ileum and other intestinal areas to the development of dysbiosis ([@B32]; [@B26]). On the other hand, a less dysbiotic environment is observed in non-affected areas of diseased subjects ([@B26]).

###### 

Changes in gut microbiota composition in inflammatory bowel disease patients.

  Microorganism (s)                           Commensal (C) or pathogenic (P) microorganisms^∗^   UC   DC
  ------------------------------------------- --------------------------------------------------- ---- ----
  Verrucomicrobia                             C                                                   ↓    ↓
  Bifidobacterium                             C                                                   ↓    ↓
  Roseburia species                           C                                                   ↓    ?
  Bacteroides                                 C                                                   ↓↑   ↑
  Firmicutes                                  C                                                   ↓    ↓
  Clostridium species (clusters IV and XIVa   C                                                   ↓    ↓↑
  *Saccharomyces cerevisiae*                  C                                                   ↓    ↓
  Pseudomonas                                 P                                                   ↓    ↓
  Proteobacteria                              P                                                   ↑    ↑
  Fusobacterium                               P                                                   ↑    ↑
  *Ruminococcus gnavus*                       P                                                   ↑    ↑
  *Candida albicans*                          P                                                   ↑    ↑

CD, Crohn's disease; UC, Ulcerative colitis.
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There is evidence suggesting dysbiosis as a cause of IBD. Environmental factors, which directly affects intestinal microbiota composition, have been pointed out as one of the key players in the pathogenesis of IBD. In this regard, early life exposure to breastfeeding and maternal smoking during pregnancy, have been inversely and positively correlated to disease outcome in CD, respectively ([@B62]). Accordingly, patients with UC ([@B24]) tend to have a better outcome when treated with microbial-based therapies (i.e., antibiotics, FMT, and probiotics). The mechanisms concerning the influence of dysbiosis in IBD outcome are still a matter of debate and investigation. Some studies suggest the association between the development of inflammation and the presence of some specific bacteria species. The reduction in strict anaerobes (e.g., *Clostridium* groups IV and XIVa), along with the expansion of facultative aerobic or aerobic bacteria, may increase the local concentration of oxygen, thus leading to augmented vascular and mucosal permeability, and promoting intestinal inflammation ([@B1]). Different strains of *Clostridium* species (e.g., IV, XIVa, and XVIII), which lack toxins and virulence factors, have their immunosuppressive activity demonstrated by inducing Treg cells in intestine in a TGF-β-, IL-10- or butyrate-dependent manner ([@B5]; [@B29]). These data suggest that microbial imbalance in IBD favors the development of inflammation by reducing crucial anti-inflammatory players, besides favoring the onset of pro-inflammatory mechanisms. On the other hand, inflammation *per se* also contributes to the onset of a dysbiotic environment. Regardless if inflammation leads to dysbiosis or vice-versa, they have a strong synergistic interaction that must be targeted to develop improved therapeutic strategies. For this reason, therapies aiming at reestablishing the microbial balance may represent the next frontier to treat inflammatory disorders, such as IBD, in which the dysbiosis plays a central role in disease pathogenesis.

Fecal Microbiota Transplantation (FMT)
======================================

Fecal microbiota transplantation has long been used to treat recurrent *Clostridium difficile* infection (CDI) presenting great effectiveness and significant safeness, with cure rates reaching 90% ([@B53]). One of the main mechanisms proposed to explain the ability of FMT to treat CDI is attributed to its capacity to restore intestinal microbial balance ([@B30]). This characteristic has expanded the use of FMT to treat both local and systemic illnesses associated with gut dysbiosis, such as irritable bowel syndrome (IBS) ([@B70]), IBD ([@B4]; [@B59]) and metabolic syndrome ([@B103]).

Because of the importance of elucidating how microbiota donors are selected and how FMT is delivered to recipients, these aspects will be clarified first. Then, we are going to present and discuss the most important scientific studies regarding the therapeutic use of FMT in IBD (Table [2](#T2){ref-type="table"}).

###### 

Clinical trials of fecal microbiota transplantation for inflammatory bowel disease.

  Authors   Diagnosis   Number of patients (P) or studies (S)^∗\ \#^   FMT route            Therapeutic regimen^&^                                      Outcome
  --------- ----------- ---------------------------------------------- -------------------- ----------------------------------------------------------- ---------------------------------------------------------------------------------------
  [@B77]    UC          *n* = 41 (S)                                   N.A                  N.A                                                         33% of clinical remission
            CD          *n* = 11 (S)                                   N.A                  N.A                                                         52% of clinical remission
  [@B71]    UC          *n* = 70 (P)                                   Enema                50 g offeces/300 mL of water; once weekly for 6 weeks       24% of clinical remission
  [@B76]    UC          *n* = 85 (P)                                   Enema                150 mL^\$^; once a day, 5 days per week for 8 weeks         27% of clinical and endoscopic remission or response
  [@B84]    UC          *n* = 50 (P)                                   Naso-duodenal tube   60 g of feces/500 mL of saline; two doses (days 0 and 21)   No statistical difference between control and treated patients
  [@B101]   CD          *n* = 19 (P)                                   Colonoscopy          50 g of feces/250 mL of saline; one dose                    58% of clinical response (control group not included)
  [@B17]    CD          *n* = 30 (P)                                   Endoscopy            150--200 mL^\$^; one dose                                   86.7 and 76.7% of clinical improvement and remission, respectively at week 4
  [@B94]    CD          *n* = 9 (P)                                    Nasogastric tube     30 g of feces/100 or 200 mL of saline; one dose             77.77% of clinical remission at week 2 55.55% of clinical remission at weeks 6 and 12

CD, Crohn's disease; N.A, Not applicable; UC, Ulcerative colitis.

\*

Both total number of patients for clinical trials and number of studies for systematic analysis or meta-analysis were included.

\#

Includes the number of control patients.

&

Feces may have undergone additional steps for FMT samples preparation.

\$

Initial solution concentration is not available.

FMT Donor Screening and Routes of Administration
------------------------------------------------

Several aspects must be considered in the search for microbiota donors. Prior to the gut microbial sequencing *per se*, a putative donor must be screened for the presence of infectious agents in feces, including *C. difficile*, intestinal parasites and virus (e.g., Norovirus) ([@B75]). In blood, aside from the complete blood count, electrolytes, liver, and kidney function tests, the presence of inflammatory markers, and transmissible infectious agents such as HIV, Hepatitis, HTLV, among others, must be performed ([@B75]). Further, as inclusion criteria, the donor must have no history of suggestive GIT disease, no other major active comorbidities, and preferably, no use of medications, especially, antimicrobials ([@B75]; [@B42]). To ensure that only healthy donors will be selected, additional criteria of exclusion must be used as follows: any family history of colorectal cancer affecting first-degree relatives; use of probiotics 3 months prior the donation period; household members with active GIT infections; any personal or familial history of malignancies, malnutrition, obesity, neurological, or developmental disorders ([@B75]; [@B42]). The difficulties to select FMT donors that fulfills all the stringency criteria along with the costs involved in the screening process have created some important barriers for the broader utilization of this microbial therapeutic approach. Unfortunately, this scenario has stimulated patients to perform FMT in a "homemade" fashion, using inappropriate screened donors, without medical supervision, which often result in serious complications ([@B41]).

For a long time, retention enema was the most used technique for FMT. However, alternative approaches have been used in this regard, including nasogastric tube, capsules, colonoscopy, and self-administered enemas, as previously reviewed ([@B3]). Colonoscopy and retention enema are by far, the most frequently used routes of FMT administration ([@B36]).

FMT in IBD
----------

Ulcerative colitis and Crohn's disease are the major entities represented by IBD. The role of FMT has been more explored in the former. From the 307 adult patients pooled in a meta-analysis from 24 UC cohort studies, FMT induced remission in 33%. In 6 pediatric cohort studies, totalizing 34 UC patients, clinical remission was slightly reduced to 23% ([@B77]). Three randomized controlled trials also presented promising results regarding the use of FMT to treat UC. From a total of 70 UC patients with active disease without infectious diarrhea enrolled in the study, 36 were treated with FMT, and 34 with placebo, once a week for a total of 6 weeks, and remission was induced in 24% of those treated with FMT compared to 5% in the placebo group ([@B71]). It is important to mention that both placebo and FMT groups were under concomitant anti-inflammatory/immunosuppressive therapy (e.g., corticosteroids, mesalamine, and anti-TNF therapy) while enrolled in the study ([@B71]). Similar results were observed using enemas 5 days per week for 8 weeks, in a study in Australia that observed a remission rate of 27% in UC patients with active UC treated with FMT when compared to 8% in patients treated with placebo only ([@B76]). Regardless if patients had received FMT or not, they were also treated with immunosuppressive drugs such as 5-aminosalicylates, thiopurines, methotrexate, and/or oral prednisone, in a stable dose ([@B76]). On the other hand, the remission rates observed in UC patients treated with FMT from healthy donors were similar to those observed in UC patients receiving their own fecal microbiota ([@B84]).

Unfortunately, data supporting the role of FMT in CD are scarcer than in UC, and so far, no results from randomized clinical trials are available. The evidence of the beneficial effects of FMT in CD are all derived from small and uncontrolled studies. A single dose of FMT performed by colonoscopy showed an improvement in clinical outcome of 58% of patients treated with FMT ([@B101]). This observation was followed by increased levels of Tregs in recipients' lamina propria followed by higher microbial diversity ([@B101]), which suggests a reestablishment of microbial balance and a less prominent inflammation. Similarly, a single treatment with FMT induced clinical improvement and remission based on clinical activity in CD patients ([@B17]). This amelioration was followed by increased patient's body weight after FMT ([@B17]). For all CD-patients enrolled in the study a 12-week washout period was required for those exposed to immunosuppressive therapies such as cyclosporine, tacrolimus, or infliximab. Antibiotics and probiotics were withdrawn 60 and 30 days before FMT, respectively ([@B101]). The beneficial role of FMT was also addressed in young patients with CD. Nine individuals, aged 12--19 years, presenting mild-to-moderate symptoms received FMT by nasogastric tube once and were followed by 12 weeks ([@B94]). Based on the clinical score, 2 weeks after FMT, 7 of 9 patients were in remission, and 5 of 9 patients were in remission at 6 and 12 weeks after FMT. All patients enrolled in the study were allowed to receive immunomodulators during the FMT or placebo treatment ([@B94]).

Limitations in FMT Studies
--------------------------

The studies presented here showed promising results regarding the use of FMT to induce remission in UC and to a less extent in CD patients. The differences in the route and interval of administration, besides of the composition and bacterial load in FMT, may explain the dissimilarities observed among studies. Another important drawback is the lack of comprehensive guidelines to be used globally in the screening and standardization of putative microbiota donors (age, gender, and health status) along with strategies of production, dosage regimen and to evaluate the transplant engraftment. Further, probably because of economic reasons, clinical trials do not deeply investigate the microbial composition of fecal donors using 16S rRNA sequencing and their similarities to the recipients' microbiota. Thus, the observation of similarities between the intestinal microbiota composition of donors and recipients may dictate the successfulness of FMT engraftment. Without the proper identification of the microbial community and the total bacterial load transplanted from a healthy donor to a diseased subject, it is difficult to predict the impact of FMT in IBD or other disorders. Further, as the majority of clinical trials were conducted with concomitant use of immunomodulatory drugs, it is reasonable to assume that FMT may work better as an adjuvant therapy rather than an isolated strategy. To confirm the role of FMT in IBD, more controlled clinical trials with a great number of patients and more standardized fecal samples must be conducted. Additionally, strategies aiming at providing an intestinal microbiota rebalance using well-defined microbial species may represent an improved alternative to total FMT.

FMT Adverse Effects
-------------------

In general, up to 10% of FMT recipients present minor to mild self-limited adverse effects. The majority of them are related to disturbances in GIT such as diarrhea and abdominal discomfort/pain ([@B41]; [@B8]). Though less frequently observed, severe side effects can include IBD flares, CDI and other infections, colectomy, small bowel obstruction, pancreatitis, and even death, as recently reviewed ([@B79]; [@B47]). However, some evidences have shown no differences between FMT and control groups concerning the occurrence of undesirable effects ([@B72]). Despite the possibility of occurrence of adverse effects, FMT is considered to be safe in IBD. An in-depth screening of donors along with a broader comprehension of the physiopathology in IBD may facilitate the development of strategies to avoid the occurrence of such undesirable effects.

Probiotics
==========

Probiotics are used as safe food additives, pharmaceutical formulations or nutritional supplements defined as "live microorganisms which, when administered in adequate amounts, confer a health benefit on the host" by the World Health Organization (WHO) ([@B39]). Nevertheless, studies have pointed out that dead microorganisms or their biologically active compounds *per se* can also play protective functions, inferring that the "probiotic" definition should be revisited or other classifications implemented ([@B80]).

The underlying mechanisms of probiotics are dependent on microbial strain. Moreover, the effects of probiotic mixtures may be complementary (also referred to additive) or synergistic ([@B85]). In general, probiotic strains produce growth factors that strengthen the gut epithelium and antimicrobial substances (e.g., SCFAs, bacteriocins, hydroperoxides, bile acids, and lactic acids) that kill harmful microorganisms ([@B55]). As a consequence, cellular components (e.g., cellular wall, DNA) are released in the gut environment, which activate immune responses by enhancing the pro-inflammatory cytokines production and immunoglobulin synthesis, besides of improving macrophage and lymphocytes activity ([@B67]). In this regard, the use of *Bifidobacterium infantis* 35624 in human volunteers increased the amount of IL-10 and FoxP3^+^ cells (Treg) in the circulation ([@B38]; [@B56]). Although immune tolerance is a putative consequence of these enhancements, there is still no consensus on this matter ([@B15]).

Non-immunological benefits associated to probiotics include the digestion and absorption processes, competition with potential pathogens for nutrients and intestinal adhesion sites, pH alterations, agglutination of pathogenic microorganisms, and sequestration of metabolic toxins ([@B30]). Animal models and *in vitro* assays describe that probiotics also decrease the apoptosis, increase the mucus synthesis, tissue repair, redistribution and production of tight junctions in gut epithelial cells, thus reducing the intestinal permeability and enhancing the barrier protection and function ([@B13]; [@B109]).

Lactobacillus (e.g., *reuteri, rhamnosus, casei, acidophilus, plantarum, gasseri, paracasei, johnsonii, ghallinarum*, and *crispatus*) and Bifidobacterium (e.g., *bifidum, infantis, longum, animalis, breve, lactis*, and *adolescentis*) are the most used strains in probiotics formulations, but multispecies approach has been increasingly applied ([@B43]). Others strains commonly used include *Streptococcus* spp., *Lactococcus* spp., *Enterococcus* spp., non-pathogenic *Escherichia coli* (strain Nissle), and *Clostridium* ssp ([@B52]).

New bacteria genera and species have also been investigated showing good perspectives in preclinical trials. These bacteria are described as new-generation probiotics bringing more complexity to common probiotics in attempt to simulate FMT treatments. The new-generation probiotics comprise *Clostridium* clusters *IV, XIVa*, and *XVIII, F. prausnitzii, Akkermansia muciniphila, Bacteroides uniformis, B. fragilis*, and *Eubacterium hallii* ([@B23]). Technological limitations are current challenges for using these bacteria as probiotics. Importantly, *Clostridium* clusters XIVa and IV are described as promoters of Treg differentiation, critical for immune tolerance as described earlier ([@B6]). Indeed, these bacteria are decreased in the gut of IBD patients ([@B92]; [@B50]; [@B64]). Although the number of Tregs is increased in the gut of IBD patients, the expansion is not sufficient to restrain the inflammatory development.

Since gut microbiota is not composed only by bacteria, some formulations and studies use yeasts as probiotics in association with bacteria strains, or even in single-drug formulations. In this context, *Saccharomyces boulardii* is the most commonly used yeast strain and has several anti-inflammatory properties ([@B78]).

Criteria for New Probiotic Development
--------------------------------------

As pharmaceutical or nutraceutical products, probiotics must meet some criteria to be commercially available. Beyond efficacy, the safety properties of a given drug are the main concern of scientists and regulatory agencies ([@B20]). Bacterial and yeast strains or their derived-products have distinct levels of regulations according to their purposes and must meet the requirements outlined in published and frequently updated guidelines designed by regulatory agencies ([@B20]). They can be considered as food (food ingredient, medical food, and dietary supplement), drug (new drugs) or biological product ([@B18]).

As in FMT, safety is a priority, since some inflammatory conditions or patients under immunosuppressive therapy increase the susceptibility to infectious complications, including sepsis ([@B25]; [@B83]). Probiotics must have human origin, scientifically proven positive effects, be safe even in high-risk populations, cannot cause allergies and must present good technology properties (e.g., feasible culture and large-scale production) ([@B67]). Several *in vitro* assays may be employed at the first glance to evaluate probiotic potential, epithelium adherence, microbicide activity, ability in reducing the number of pathogenic bacteria and resistance to antibiotic use, bile salts, stomach acids, digestive enzymes and pH ([@B86]).

Although not mandatory, studies should also evaluate the adverse effects and drug interactions of probiotics since they have been used as adjuvant therapy in various diseases ([@B97]). For instance, the probiotic *E. coli* strain Nissle 1917 influences the pharmacokinetics of concomitantly taken antiarrhythmic drug amiodarone by increasing the drug bioavailability ([@B69]). Therefore, their presumed safety should be avoided, and the potential risks not neglected.

Probiotics in IBD
-----------------

In general, probiotics have been effectively used in treating IBD to prevent dysbiosis in patients undergoing prolonged antibiotic or immunosuppressive therapies ([@B108]). Further, these microorganisms have been used as adjuvant therapy on the attempt to reverse the dysbiotic environment associated with IBD onset and worsening ([@B106]; [@B96]). Although the number of clinical and experimental studies using probiotics in IBD is substantially high, lack of standard practices in therapeutic regimens, low number of samples and poor disease characterization, have limited the relevant conclusions about the efficacy of probiotics in this scenario.

Probiotics have been described as an alternative to induce and maintain the remission in UC, while low or no effects are observed in CD. The adjuvant use of multispecies probiotic VSL\#3, which contains four strains of Lactobacillus (*L. casei, L. plantarum, L. acidophilus* and *L. delbrueckii* subsp. *Bulgaricus*), three of Bifidobacterium (*B. longum, B. breve*, and *B. infantis*), and one of Streptococcus (*S. salivarius* subsp. *Thermophilus*), improved the clinical symptoms in patients with mild to moderately active UC after receiving the daily dose of 3.6 × 10^12^ CFU ([@B99]; [@B66]). Corroborating results were observed after treating mild-to-moderate UC patients with VSL\#3 alone, twice a day at the same dose described earlier ([@B93]). The maintenance of remission rates in UC was also similar in patients under single drug treatment of either non-pathogenic *E. coli* Nissle 1917 (5--50 × 10^9^/day) or mesalazine (1500 mg/day) ([@B58]).

However, the systematic review using rigorous statistical methods showed that the beneficial effects of both VSL\#3 or *E. coli* Nissle on UC are weak or inconclusive, while there is no positive association in CD ([@B48]), confirming the need for further new randomized controlled trials to increase the significance level of these findings.

The use of Bifidobacterium-fermented milk (containing *B. breve, B. bifidum*, and *L. acidophilus*) as adjuvant therapy to treat 20 patients (including placebo control) with mild to moderately active UC, showed significant improvement in both clinical and endoscopic activity indexes after 12 weeks (10 billion bacteria/day) ([@B51]). Interestingly, the SCFAs concentration in feces was higher in the probiotic-treated group compared to the placebo group. However, a recent study using a similar therapeutic strategy (*B. breve*- and *L. acidophilus*-containing fermented milk) showed no efficacy to treat or maintain the remission of UC in 195 patients ([@B68]). In fact, the use of *B. bifidum* as single strain-containing probiotic was sufficient to increase the levels of fecal SCFAs in healthy volunteers ([@B31]), however, the protective role in UC or CD remains unknown. Despite some discrepancies regarding the number of patients used in the studies mentioned above, the first was the only one to confirm the increased number of Bifidobacteria in the feces of probiotics-treated patients and to perform endoscopic analysis.

The treatment with *Lactobacillus* GG (18 × 10^9^ viable bacteria/day) alone or associated with mesalazine, prolonged the relapse-free period in UC patients compared to the group treated with immunosuppressant drug alone in a 12-month treatment regimen ([@B107]). Similarly, a systematic review of randomized clinical trials showed the use of different lactic acid bacteria and Bifidobacteria as adjuvant therapy improved the course of disease and maintenance of clinical remission in UC ([@B87]).

As stated above, probiotics have poor or no effects on CD. However, studies have yielded positive results to induce remission by associating probiotics and prebiotics (defined as symbiotics) ([@B28]; [@B87]). Additionally, one open-label pilot study containing four children with mildly to moderately active CD had a significant improvement on clinical aspects after treatment with *Lactobacillus* GG (10^10^ CFU/tablet, twice a day for 6 months) ([@B37]). However, the low number of samples and the absence of appropriate control (placebo-treated patients or under regular therapy) undermine the rigor of study. Probiotics have no effects in maintaining the remission of CD ([@B11]; [@B10]).

In conclusion, probiotics are potential options in inducing and maintaining remission of mild to moderately UC, however, seem to be ineffective in DC (Table [3](#T3){ref-type="table"}). The results must be considered as preliminary evidence and further randomized double-blind placebo-controlled multicenter trials must be performed to increase the reliability of results.

###### 

Effective clinical trials using probiotics for treating inflammatory bowel disease.

  Authors   Diagnosis   Number of patients (P) or studies (S)^∗\ \#^   Probiotic                                                      Therapeutic regimen                                               Outcome
  --------- ----------- ---------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------------------------
  [@B66]    UC          *n* = 5 (S) *n* = 441 (P)                      VSL\#3^&^                                                      Oral; 3.6 × 10^12^ CFU/day^\$^                                    53.4% of clinical responsiveness and 43.8% of clinical remission
  [@B99]    UC          *n* = 144 (P)                                  VSL\#3^&^                                                      Oral; 3.6 × 10^12^ CFU/day; once a day for 8 weeks                53.4% of clinical improvement and 47.3% of clinical remission
  [@B93]    UC          *n* = 147 (P)                                  VSL\#3^&^                                                      Oral; 3.6 × 10^12^ CFU/dose; twice a day for 12 weeks             51.9% of clinical improvement and 42.9% of clinical remission at 12 weeks
  [@B58]    UC          *n* = 327 (P)                                  *Escheria coli* Nissle 1917                                    Oral; 5--50 × 10^9^ viables bacteria; once a day for 12 months    No differences between probiotic- and mesalazine-treated groups
  [@B51]    UC          *n* = 20 (P)                                   Fermented milk (*B. breve, B. bifidum* and *L. acidophilus*)   Oral; 10^9^ bacteria/day; once a day for 12 weeks                 70% of clinical responsiveness and 40% of clinical remission
  [@B107]   UC          *n* = 187 (P)                                  *Lactobacillus* GG                                             Oral; 9 × 10^9^ viable bacteria/dose; twice a day for 12 months   No differences between probiotic- and mesalazine-treated groups
  [@B28]    CD          *n* = 10 (P)                                   *B. breve, L. asei* and *B. longum*                            Oral; 75 × 10^9^ bacteria/day; once a day for 13 (±4.5) months    70% of clinical responsiveness and 60% of clinical remission
  [@B37]    CD          *n* = 4 (P)                                    *Lactobacillus* GG                                             Oral; 10^10^ CFU/dose; twice a day for 6 months                   75% of clinical improvement at weeks 4 and 12

CD, Crohn's disease; UC: Ulcerative colitis.

\*

Both total number of patients for clinical trials and number of studies for systematic analysis or meta-analysis were included.

\#

Includes the number of control patients.

&

VSL\#3 is composed by

L. casei, L. plantarum, L. acidophilus, L. delbrueckii

subsp.

bulgaricus, B. longum, B. breve, B. infantis

and

Streptococcus sulivarius

subsp.

thermophiles.

\$

Length of treatments not available.

Limitations on Probiotics Studies
---------------------------------

Different therapeutic regimen (including dose and frequency of administration) is an important problem to design treatment protocols. Although doses vary according to bacterial strains, studies have shown that 10^8^--10^10^ CFU/day are ingested after consuming 100 mL or 100 g of probiotic-containing product ([@B6]). As a consequence, meta-analysis studies have several biases to compare related clinical trials and to draw relevant conclusions.

Unlike FMT therapy, the route of administration is not a potential problem, since the majority of studies use the oral route as the main one, although enemas are also a potential method of probiotic delivery ([@B73]).

Another important issue regarding probiotics formulations is the quality control. Several inconsistent data have been described between label information and product content, contamination, poor quality of strains, among others, as previously reviewed ([@B54]). Moreover, the same strain may show different efficacy in distinct batches as a result of a lack of standardization in bacterial culture procedures used throughout the studies and manufactures. Thus, both guidelines and improvements on supervision are highly encouraged to provide sufficient information on the design of new studies and to prevent unwanted and conflicting outcomes.

The immunosuppressive therapy is also a current challenge for clinicians and researchers. Since long-term use of immunosuppressants causes dysbiosis, it is important to determine whether this factor is a premise for the patient's responsiveness to probiotic treatment ([@B9]).

Altogether, these factors represent important limitations in studies setup and the conflicting clinical results found in the literature may derive from poorly designed and standardized studies.

Conclusion and Further Directions
=================================

Both FMT and probiotics are therapies with good prospects in the medical field, especially in IBD. However, like other newly developed therapies, the challenges encountered for increasing the reliability, safety, and standardization of FMT and probiotics are considerable. Thus, more multicenter studies must be performed to increase the number of samples and variables (features of IBD, phenotypic and genotypic characteristics of the patients, standardizations in the therapeutic regimen, etc.), generating more significant conclusions.
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